This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eisai Co., Ltd.
Drug Names(s): dalteparin
Description: Fragmin is a low molecular weight heparin. Like heparin, Fragmin prevents blood clots from forming. It works by blocking the action of two of the 12 proteins in blood (factors X and to a lesser degree factor II) whose action is necessary in order for blood to clot. It acts mainly by accelerating the rate of the neutralization of coagulation factors by antithrombin, but other mechanisms may also be involved.
Deal Structure: In September 2005, Eisai signed an in-license agreement with Pfizer for exclusive U.S. rights to promote FRAGMIN. Eisai also will assume responsibility for post-marketing studies and product distribution, as well as book all U.S. sales. According to this agreement, Pfizer will transfer the New Drug Application for FRAGMIN to Eisai for the duration of the deal.
Partners: Pfizer Inc.
Pink Sheet In Brief: Pharmacia & Upjohn's Fragmin
Pink Sheet In Brief: Pharmacia & Upjohn Fragmin
Additional information available to subscribers only: